EGFR and non-small cell lung carcinoma: Improved and composite biomarkers in the future could not only help to evaluate the functional activity of c-MET protein accurately but also use alternative indicators such as MET gene alterations and EGFR mutations to precisely determine the type of NSCLC (105).